Functionally characterizing the noncoding genome of metastatic prostate cancer to identify therapeutic vulnerabilities
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2110234
- Recipient
-
Dana-Farber Cancer Institute, Inc. UEI DPMGH9MG1X67
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $945,271
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $945,271 project grant to Dana-Farber Cancer Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The three-year award beginning July 1, 2021 will fund research to functionally characterize the noncoding genome of metastatic prostate cancer and identify therapeutic vulnerabilities. Dana-Farber will work with Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis to construct a CRISPR-Cas9 barcoded library, introduce candidate somatic mutations identified in cell lines, and test relevant enhancers and mutations in vivo using xenograft mouse models. The sub-awardee collaboration aims to advance understanding of metastasis-specific gene regulation and castration resistance to improve prostate cancer treatment outcomes.
Quick answers
Who received award W81XWH2110234?
W81XWH2110234 was awarded to Dana-Farber Cancer Institute, Inc. by Medical Command (Department of the Army) on July 1, 2021.
How much is award W81XWH2110234 worth?
$945,271 has been obligated on W81XWH2110234.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award